Literature DB >> 27025858

Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?

Michela Buglione1, Sara Pedretti2, Pietro Luigi Poliani3, Roberto Liserre4, Stefano Gipponi5, Giannantonio Spena6, Paolo Borghetti2, Ludovica Pegurri2, Federica Saiani7, Luigi Spiazzi7, Giulia Tesini7, Chiara Uccelli7, Luca Triggiani2, Stefano Maria Magrini2.   

Abstract

To analyse the pattern of recurrence of patients treated with Stupp protocol in relation to technique, to compare in silico plans with reduced margin (1 cm) with the original ones and to analyse toxicity. 105 patients were treated: 85 had local recurrence and 68 of them were analysed. Recurrence was considered in field, marginal and distant if >80 %, 20-80 % or <20 % of the relapse volume was included in the 95 %-isodose. In silico plans were retrospectively recalculated using the same technique, fields angles and treatment planning system of the original ones. The pattern of recurrence was in field, marginal and distant in 88, 10 and 2 % respectively and was similar in in silico plans. The margin reduction appears to spare 100 cc of healthy brain by 57 Gy-volume (p = 0.02). The target coverage was worse in standard plans (pt student < 0.001), especially if the tumour was near to organs at risk (pχ2 < 0.001). PTV coverage was better with IMRT and helical-IMRT, than conformal-3D (pAnova test = 0.038). This difference was no more significant with in silico planning. A higher incidence of asthenia and leuko-encephalopathy was observed in patients with greater percentage of healthy brain included in 57 Gy-volume. No differences in the pattern of recurrence according to margins were found. The margin reduction determines sparing of healthy brain and could possibly reduce the incidence of late toxicity. Margin reduction could allow to use less sophisticated techniques, ensuring appropriate target coverage, and the choice of more costly techniques could be reserved to selected cases.

Entities:  

Keywords:  Glioblastoma; Margin reduction; Radio-induced late toxicity; Radiotherapy techniques

Mesh:

Year:  2016        PMID: 27025858     DOI: 10.1007/s11060-016-2112-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  50 in total

1.  A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.

Authors:  Robert B Den; Mitchell Kamrava; Zhi Sheng; Maria Werner-Wasik; Erin Dougherty; Michelle Marinucchi; Yaacov R Lawrence; Sarah Hegarty; Terry Hyslop; David W Andrews; Jon Glass; David P Friedman; Michael R Green; Kevin Camphausen; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

2.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.

Authors:  Brian J Gill; David J Pisapia; Hani R Malone; Hannah Goldstein; Liang Lei; Adam Sonabend; Jonathan Yun; Jorge Samanamud; Jennifer S Sims; Matei Banu; Athanassios Dovas; Andrew F Teich; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Peter A Sims; Peter Canoll
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

3.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

4.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

5.  Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage.

Authors:  M P Mehta; J Masciopinto; J Rozental; A Levin; R Chappell; K Bastin; J Miles; P Turski; S Kubsad; T Mackie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

Review 6.  Epidemiology of brain tumors.

Authors:  James L Fisher; Judith A Schwartzbaum; Margaret Wrensch; Joseph L Wiemels
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

7.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

8.  Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

Authors:  Hans Skovgaard Poulsen; Kirsten Grunnet; Morten Sorensen; Preben Olsen; Benedikte Hasselbalch; Knud Nelausen; Michael Kosteljanetz; Ulrik Lassen
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

9.  αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.

Authors:  Anne Ducassou; Emmanuelle Uro-Coste; Pierre Verrelle; Thomas Filleron; Alexandra Benouaich-Amiel; Vincent Lubrano; Jean-Christophe Sol; Marie-Bernadette Delisle; Gilles Favre; Solea Ken; Anne Laprie; Peter De Porre; Christine Toulas; Muriel Poublanc; Elizabeth Cohen-Jonathan Moyal
Journal:  Eur J Cancer       Date:  2013-04-06       Impact factor: 9.162

10.  Incidence trends of adult primary intracerebral tumors in four Nordic countries.

Authors:  Stefan Lönn; Lars Klaeboe; Per Hall; Tiit Mathiesen; Anssi Auvinen; Helle C Christensen; Christoffer Johansen; Tiina Salminen; Tore Tynes; Maria Feychting
Journal:  Int J Cancer       Date:  2004-01-20       Impact factor: 7.396

View more
  12 in total

1.  The growing role of biology in the treatment of glioblastoma: no more one kind of disease.

Authors:  Michela Buglione; Luca Triggiani; Stefano Maria Magrini
Journal:  J Neurooncol       Date:  2017-04-20       Impact factor: 4.130

2.  Is there a potential role for EGFR expression to lead margin reduction in glioblastoma?

Authors:  Paolo Tini; Valerio Nardone; Luigi Pirtoli
Journal:  J Neurooncol       Date:  2017-04-05       Impact factor: 4.130

3.  NRG brain tumor specialists consensus guidelines for glioblastoma contouring.

Authors:  Tim J Kruser; Walter R Bosch; Shahed N Badiyan; Joseph A Bovi; Amol J Ghia; Michelle M Kim; Abhishek A Solanki; Sean Sachdev; Christina Tsien; Tony J C Wang; Minesh P Mehta; Kevin P McMullen
Journal:  J Neurooncol       Date:  2019-03-19       Impact factor: 4.130

4.  Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.

Authors:  Xiaowen Sun; Lei Deng; You Lu
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

5.  Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Authors:  Supriya Mallick; Haresh Kunhiparambath; Subhash Gupta; Rony Benson; Seema Sharma; M A Laviraj; Ashish Datt Upadhyay; Pramod Kumar Julka; Dayanand Sharma; Goura Kishor Rath
Journal:  J Neurooncol       Date:  2018-06-23       Impact factor: 4.130

6.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

7.  Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis.

Authors:  Guixiang Liao; Zhihong Zhao; Hongli Yang; Xianming Li
Journal:  Front Oncol       Date:  2019-10-14       Impact factor: 6.244

8.  Spatial distribution of malignant transformation in patients with low-grade glioma.

Authors:  Asgeir S Jakola; David Bouget; Ingerid Reinertsen; Anne J Skjulsvik; Lisa Millgård Sagberg; Hans Kristian Bø; Sasha Gulati; Kristin Sjåvik; Ole Solheim
Journal:  J Neurooncol       Date:  2020-01-09       Impact factor: 4.130

9.  Limited recurrence distance of glioblastoma under modern radiotherapy era.

Authors:  Ziwei Tu; Huifen Xiong; Yang Qiu; Guoqing Li; Li Wang; Shiyi Peng
Journal:  BMC Cancer       Date:  2021-06-22       Impact factor: 4.430

10.  Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage?

Authors:  Tommy Sheu; Tina M Briere; Adenike M Olanrewaju; Mary Frances McAleer
Journal:  Adv Radiat Oncol       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.